Using the pre-amplification method, tumor-derived mutant KRAS in the plasma of patients with resectable PDAC was accurately detected (AUC, 0.861–0.876), and the dPCR method improved post-resection recurrence prediction over that of the marker CA19-9 [26]. This evidence concerns the gene KRAS and neoplasm.